Novartis released promising interim Phase II data of iptacopan in C3 glomerulopathy (C3G) at the virtual American Society of Nephrology 2020 Annual Meeting.
Alexion Pharmaceuticals shuttered the company’s oral small molecule Factor D inhibitor program for a rare kidney disease following disappointing clinical data.
AstraZeneca reported successful results from the company’s Phase III DAPA-CKD clinical trial of Farxiga (dapagliflozin) in end-stage kidney disease.
The U.S. Food and Drug Administration accepted the filing of Aurinia Pharmaceuticals Inc.’s New Drug Application (NDA) for voclosporin as a potential treatment for lupus nephritis, a serious inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus.
A new campaign from Horizon Therapeutics called Down and Out Kidney sheds light on the prevalence and impact of gout in chronic kidney disease, and aims to facilitate an important conversation with nephrologists – kidney specialists – particularly during National Kidney Month (March).
Pharma companies from across the globe provide updates on their pipelines and business.
Swiss company Vifor Pharma and Germany’s Evotec AG launched a joint venture to focus on the discovery and development of new therapies for kidney diseases.
Invokana won U.S. approval to reduce the risk of end-stage kidney disease, cardiovascular death and worsening of kidney function in adults with type 2 diabetes and diabetic kidney disease.
British Columbia-based Chinook Therapeutics burst onto the scene with $65 million in hand and a goal of driving a portfolio of compounds aimed at kidney diseases into the clinic by 2021.
The Trump administration plans to change the way it pays for kidney disease treatments to favor lower cost care at home and transplants over the current standard, dialysis clinics, top health officials said during a press briefing.
